Open Book Extracts Launches Randomized Placebo-Controlled Trial Of THCV And Rare Cannabinoids For Focus And Energy

Open Book Extracts, announced the launch of its third trial on rare cannabinoids, in partnership with Radicle Science.

Radicle Science is conducting the four-week blinded, randomized, placebo-controlled, institutional review board approved trial comparing the effects of various OBX cannabinoid formulations including THCV on energy and focus, as well as other outcomes such as well-being, feelings of anxiety, and pain.

"We are excited to continue to partner with OBX to conduct rigorous human research to better understand the effects of rare cannabinoids on health outcomes. This latest study involves a large and diverse population of nearly 1,000 individuals from across the USA and employs gold-standard rigorous clinical research design; it is a blinded randomized, placebo-controlled trial of cannabinoids for energy and focus. This groundbreaking study also represents one of the first and largest randomized controlled trials on the impact of rare cannabinoids like THCV on energy and focus levels," stated Dr. Jeff Chen, MD/MBA, co-founder and CEO of San Diego-based Radicle Science.

Results from the study are expected in early 2023.

Earlier this year, OBX and Radicle Science completed blinded, randomized, controlled trials to study the effects of rare cannabinoids on pain and sleep, and Radicle Science and OBX are planning future clinical trials on the effectiveness of rare cannabinoids on a variety of additional health outcomes.

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo by Esteban Lopez on Unsplash

Related News

Step Away Cannabis, Purissima Launches Fermentation-Derived Natural CBC From Microalgae Via OBX

Open Book Extracts Teams Up With Day Three Labs To Launch Cannabis Edibles Featuring Its Unlokt Delivery Technology